摘要
目的:探讨替格瑞洛与氯吡格雷对冠心病介入治疗患者炎症水平、心功能及心血管不良事件的影响。方法:选取2017年7月-2019年7月于本院行介入治疗的88例冠心病患者,按随机数字表法分为对照组和观察组,各44例。对照组采用氯吡格雷治疗,观察组采用替格瑞洛治疗。比较两组炎症反应、心功能指标、心血管不良事件及不良反应发生状况。结果:两组治疗前炎症反应、心功能指标相比,差异无统计学意义(P>0.05);观察组治疗后IL-6、CRP及TNF-α水平分别为(12.64±1.63)ng/L、(2.24±0.28)mg/L、(1.31±0.15)ng/L,均低于对照组,差异有统计学意义(P<0.05);观察组治疗后LVEDD为(50.21±5.05)mm,低于对照组,LVEF水平为(56.23±5.82)%,高于对照组,差异有统计学意义(P<0.05);观察组心血管不良事件发生率为4.55%,低于对照组的20.45%,差异有统计学意义(P<0.05);两组均无严重不良反应。结论:相比于氯吡格雷,替格瑞洛可改善冠心病介入治疗患者炎症状态,增强心功能,降低心血管不良事件发生率。
Objective:To investigate the effects of Ticagrelor and Clopidogrel on inflammation level,cardiac function and cardiovascular adverse events in patients with coronary heart disease intervention therapy.Method:A total of 88 patients with coronary heart disease who underwent interventional therapy in our hospital from July 2017 to July 2019 were selected and divided into the control group and the observation group with random number table method,each with 44 cases.The control group was treated with Clopidogrel,and the observation group was treated with Ticagrelor.The inflammatory response,cardiac function indexes,cardiovascular adverse events and the occurrence of adverse reactions were compared between the two groups.Result:There were no significant differences between the two groups before the treatment of inflammation response and cardiac function indexes(P>0.05);the levels of IL-6,CRP and TNF-αin the observation group after treatment were respectively(12.64±1.63)ng/L,(2.24±0.28)mg/L,(1.31±0.15)ng/L,lower than those of the control group,the difference was statistically significant(P<0.05);the level of LVEDD in the observation group after treatment was(50.21±5.05)mm,which was lower than that of the control group;LVEF level was(56.23±5.82)%,which was higher than that of the control group,the differences were statistically significant(P<0.05).The incidence of cardiovascular adverse events in the observation group was 4.55%,which was lower than 20.45%of the control group,the difference was statistically significant(P<0.05).There were no serious adverse reactions in both groups.Conclusion:Compared with Clopidogrel,Ticagrelor can improve the inflammatory state of patients with coronary heart disease intervention therapy,enhance cardiac function,and reduce the incidence of cardiovascular adverse events.
作者
孙文超
韩俊愈
李卫华
SUN Wenchao;HAN Junyu;LI Weihua(The First Affiliated Hospital of Xiamen University,Xiamen 361000,China)
出处
《中外医学研究》
2020年第30期3-5,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
冠心病
替格瑞洛
氯吡格雷
炎症反应
心血管不良事件
Coronary heart disease
Ticagrelor
Clopidogrel
Inflammatory response
Cardiovascular adverse events
